vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and FNB CORP (FNB). Click either name above to swap in a different company.

FNB CORP is the larger business by last-quarter revenue ($366.0M vs $196.0M, roughly 1.9× Axsome Therapeutics, Inc.). FNB CORP runs the higher net margin — 45.9% vs -14.6%, a 60.5% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 13.7%). FNB CORP produced more free cash flow last quarter ($99.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 7.1%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

FNB Corporation is a diversified financial services corporation based in Pittsburgh, Pennsylvania, and the holding company for its largest subsidiary, First National Bank. As of December 31, 2025, FNB has total assets of more than $50 billion. FNB's market coverage spans several major metropolitan areas, including Pittsburgh, Pennsylvania; Baltimore, Maryland; Cleveland, Ohio; Washington, D.C.; Charlotte, Raleigh, Durham and the Piedmont Triad in North Carolina; and Charleston, South Carolina...

AXSM vs FNB — Head-to-Head

Bigger by revenue
FNB
FNB
1.9× larger
FNB
$366.0M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+51.4% gap
AXSM
65.0%
13.7%
FNB
Higher net margin
FNB
FNB
60.5% more per $
FNB
45.9%
-14.6%
AXSM
More free cash flow
FNB
FNB
$117.7M more FCF
FNB
$99.0M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
7.1%
FNB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
FNB
FNB
Revenue
$196.0M
$366.0M
Net Profit
$-28.6M
$168.0M
Gross Margin
Operating Margin
-13.8%
45.1%
Net Margin
-14.6%
45.9%
Revenue YoY
65.0%
13.7%
Net Profit YoY
61.9%
52.7%
EPS (diluted)
$-0.55
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
FNB
FNB
Q4 25
$196.0M
$366.0M
Q3 25
$171.0M
$359.0M
Q2 25
$150.0M
$348.0M
Q1 25
$121.5M
$323.0M
Q4 24
$118.8M
$322.0M
Q3 24
$104.8M
$323.0M
Q2 24
$87.2M
$316.0M
Q1 24
$75.0M
$319.0M
Net Profit
AXSM
AXSM
FNB
FNB
Q4 25
$-28.6M
$168.0M
Q3 25
$-47.2M
$150.0M
Q2 25
$-48.0M
$130.0M
Q1 25
$-59.4M
$117.0M
Q4 24
$-74.9M
$110.0M
Q3 24
$-64.6M
$110.0M
Q2 24
$-79.3M
$123.0M
Q1 24
$-68.4M
$122.0M
Operating Margin
AXSM
AXSM
FNB
FNB
Q4 25
-13.8%
45.1%
Q3 25
-27.0%
52.9%
Q2 25
-24.5%
47.7%
Q1 25
-46.9%
45.8%
Q4 24
-61.1%
31.7%
Q3 24
-59.8%
43.3%
Q2 24
-89.5%
49.7%
Q1 24
-89.7%
48.9%
Net Margin
AXSM
AXSM
FNB
FNB
Q4 25
-14.6%
45.9%
Q3 25
-27.6%
41.8%
Q2 25
-32.0%
37.4%
Q1 25
-48.9%
36.2%
Q4 24
-63.1%
34.2%
Q3 24
-61.7%
34.1%
Q2 24
-91.0%
38.9%
Q1 24
-91.1%
38.2%
EPS (diluted)
AXSM
AXSM
FNB
FNB
Q4 25
$-0.55
$0.47
Q3 25
$-0.94
$0.41
Q2 25
$-0.97
$0.36
Q1 25
$-1.22
$0.32
Q4 24
$-1.54
$0.31
Q3 24
$-1.34
$0.30
Q2 24
$-1.67
$0.34
Q1 24
$-1.44
$0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
FNB
FNB
Cash + ST InvestmentsLiquidity on hand
$322.9M
$2.5B
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$88.3M
$6.8B
Total Assets
$689.8M
$50.2B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
FNB
FNB
Q4 25
$322.9M
$2.5B
Q3 25
$325.3M
$2.4B
Q2 25
$303.0M
$2.4B
Q1 25
$300.9M
$2.4B
Q4 24
$315.4M
$2.4B
Q3 24
$327.3M
$2.1B
Q2 24
$315.7M
$1.9B
Q1 24
$331.4M
$1.5B
Total Debt
AXSM
AXSM
FNB
FNB
Q4 25
$1.9B
Q3 25
$2.1B
Q2 25
$2.7B
Q1 25
$2.5B
Q4 24
$3.0B
Q3 24
$2.5B
Q2 24
$2.0B
Q1 24
$2.1B
Stockholders' Equity
AXSM
AXSM
FNB
FNB
Q4 25
$88.3M
$6.8B
Q3 25
$73.7M
$6.6B
Q2 25
$73.1M
$6.5B
Q1 25
$53.2M
$6.4B
Q4 24
$57.0M
$6.3B
Q3 24
$92.9M
$6.2B
Q2 24
$102.9M
$6.1B
Q1 24
$144.0M
$6.0B
Total Assets
AXSM
AXSM
FNB
FNB
Q4 25
$689.8M
$50.2B
Q3 25
$669.3M
$49.9B
Q2 25
$639.8M
$49.7B
Q1 25
$596.7M
$49.0B
Q4 24
$568.5M
$48.6B
Q3 24
$561.5M
$48.0B
Q2 24
$548.2M
$47.7B
Q1 24
$545.7M
$45.9B
Debt / Equity
AXSM
AXSM
FNB
FNB
Q4 25
0.28×
Q3 25
0.32×
Q2 25
0.41×
Q1 25
0.39×
Q4 24
0.48×
Q3 24
0.40×
Q2 24
0.33×
Q1 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
FNB
FNB
Operating Cash FlowLast quarter
$-18.7M
$128.0M
Free Cash FlowOCF − Capex
$-18.7M
$99.0M
FCF MarginFCF / Revenue
-9.6%
27.0%
Capex IntensityCapex / Revenue
0.0%
7.9%
Cash ConversionOCF / Net Profit
0.76×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$376.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
FNB
FNB
Q4 25
$-18.7M
$128.0M
Q3 25
$1.0M
$167.0M
Q2 25
$-32.4M
$123.0M
Q1 25
$-43.4M
$64.0M
Q4 24
$-26.2M
$326.0M
Q3 24
$-18.6M
$-14.0M
Q2 24
$-30.1M
$85.0M
Q1 24
$-53.5M
$245.0M
Free Cash Flow
AXSM
AXSM
FNB
FNB
Q4 25
$-18.7M
$99.0M
Q3 25
$988.0K
$149.0M
Q2 25
$-32.4M
$85.0M
Q1 25
$-43.7M
$43.0M
Q4 24
$-26.2M
$278.0M
Q3 24
$-18.7M
$-46.0M
Q2 24
$-30.2M
$55.0M
Q1 24
$-53.6M
$216.0M
FCF Margin
AXSM
AXSM
FNB
FNB
Q4 25
-9.6%
27.0%
Q3 25
0.6%
41.5%
Q2 25
-21.6%
24.4%
Q1 25
-36.0%
13.3%
Q4 24
-22.1%
86.3%
Q3 24
-17.9%
-14.2%
Q2 24
-34.6%
17.4%
Q1 24
-71.4%
67.7%
Capex Intensity
AXSM
AXSM
FNB
FNB
Q4 25
0.0%
7.9%
Q3 25
0.0%
5.0%
Q2 25
0.0%
10.9%
Q1 25
0.3%
6.5%
Q4 24
0.0%
14.9%
Q3 24
0.1%
9.9%
Q2 24
0.1%
9.5%
Q1 24
0.1%
9.1%
Cash Conversion
AXSM
AXSM
FNB
FNB
Q4 25
0.76×
Q3 25
1.11×
Q2 25
0.95×
Q1 25
0.55×
Q4 24
2.96×
Q3 24
-0.13×
Q2 24
0.69×
Q1 24
2.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons